Amylyx Q1 net product revenue $71.4M; net income $1.6M vs $47.8M loss YoY

Amylyx Pharmaceuticals, Inc.

2023-Q1 EPS reported $0.02 revenue$71,428,000

Net product revenue $71.4M from RELYVRIO/ALBRIOZA ALS sales; cost of sales $5.3M.
Net income $1.6M ($0.02/share) vs net loss $47.8M ($0.93/share) in Q1 2022.
Cash and investments $345.7M at March 31, 2023, down slightly from $346.9M at Dec 31, 2022.
Phase 3 PHOENIX ALS trial fully enrolled (664 participants); topline results expected mid-2024.
Plans to initiate global Phase 3 trial of AMX0035 in progressive supranuclear palsy in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amylyx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $71.4 million, net income $1.6 million, or $0.02 per share, EPS $0.02 per share.

Period: the first quarter ended March 31, 2023
Revenue: $71.4 million
Net income: $1.6 million, or $0.02 per share
EPS: $0.02 per share
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO ® in U.S. and ALBRIOZATM in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline

View on SEC.gov

Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.